| Original language | English |
|---|---|
| Pages (from-to) | 56-58.e1 |
| Number of pages | 3 |
| Journal | Medical Journal of Australia |
| Volume | 215 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Jul 2021 |
Bibliographical note
Funding Information:To find effective therapeutic options for COVID‐19, various approaches to coordination and prioritisation of clinical research have been taken globally. There are more than 3000 relevant RCTs now registered. Among these, the key practice‐changing trials have been well coordinated, pragmatic, publicly supported by government, and funded by national research agencies. The standout examples are the Randomised Evaluation of COVID‐19 Therapy (RECOVERY) trial in the United Kingdom; the “Solidarity” clinical trial for COVID‐19 treatments, run by the World Health Organization (WHO); the Adaptive COVID‐19 Treatment Trial (ACTT) in the United States; and the Randomised, Embedded, Multi‐factorial, Adaptive Platform Trial for Community‐Acquired Pneumonia (REMAP‐CAP), which involves participating sites in 21 countries. In addition, the prior development of national clinical research networks and infrastructure for improved patient care has strengthened pandemic responsiveness. For example, the UK National Institute for Health Research, with a hospital‐based trial infrastructure of clinical research units, was recruiting > 2000 patients per day to RCTs before COVID‐19. When COVID‐19 trials were prioritised in the UK, the existing infrastructure was ready to support pragmatic studies such as RECOVERY and REMAP‐CAP. Almost 40 000 participants have been randomised in RECOVERY, and the UK has been the best recruiting nation globally for REMAP‐CAP (with > 4400 of > 6000 participants recruited). 3 4 5 6 7 8 9 5 8
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
